Caribou Shares Positive Data from ANTLER Trial in B-NHL; Pfizer Invests in Caribou’s BCMA-targeting Cell Therapies
On Thursday, July 13, Caribou held a virtual event to report follow-up data from CB-010’s (allogeneic CD19 CAR-T) Ph1 ANTLER trial for patients with ≥2L B-NHL (press release / presentation). Notably, the news came a week after Pfizer made a $25M equity investment in Caribou to advance CB-011 (allogeneic BCMA CAR-T) program (press release, Jul 6, 2023). Below, Celltelligence provides insights on CB-010’s clinical results and Caribou’s plans to discuss with the FDA the initiation of a pivotal trial in 2L LBCL, while discussing Pfizer’s investment in Caribou’s allogeneic asset for MM.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.